InvOpps GP IV, L.L.C. - Jan 3, 2023 Form 4 Insider Report for Oyster Point Pharma, Inc. (OYST)

Role: Director, 10%+ Owner
Signature: INVOPPS IV US, L.P., By: InvOpps GP IV, L.L.C., its general partner, By: /s/ Sacha Lainovic, Name: Sacha Lainovic, Title: Managing Member
Stock symbol: OYST
Transactions as of: Jan 3, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/5/2023, 03:30 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OYST	Common Stock, par value $0.001 per share	Disposition pursuant to a tender of shares in a change of control transaction		-918K	-100%		0	Jan 3, 2023	See Footnotes	F1, F2, F4, F5
transaction	OYST	Common Stock, par value $0.001 per share	Disposition pursuant to a tender of shares in a change of control transaction		-1.85M	-100%		0	Jan 3, 2023	See Footnotes	F1, F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

InvOpps GP IV, L.L.C. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement") by and among Viatris Inc. ("Viatris") and Viatris's wholly owned subsidiary, Iris Purchaser Inc. dated as of November 7, 2022, these shares of common stock, par value $0.001 per share were tendered prior to the Offer Expiration Time (as defined in the Merger Agreement) and disposed of at the Effective Time (as defined in the Merger Agreement) in exchange for the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.
F2	Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US").
F3	Reflects securities directly held by InvOpps IV, L.P. ("Invus IV").
F4	InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP.
F5	Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.